Melissa L. Jampol, a Member of the Firm in the Health Care and Life Sciences and Litigation practices, in the firm’s New York office, was quoted in the Bloomberg BNA Health Care Daily Report, in “DOJ Guidance a Measuring Stick for Compliance Programs,” by Eric Topor. (Read the full version – subscription required.)
Following is an excerpt:
Melissa L. Jampol with Epstein Becker & Green saw a connection between the timing of the guidance and the confirmation of Jeff Sessions as attorney general on Feb. 8. Jampol, a New York member in the firm's life sciences practice, told Bloomberg BNA Feb. 22 the guidance's release signals the DOJ's intention to continue its current course of pursuing health-care fraud, especially in light of the monetary return generated from health-care fraud enforcement and the growing share of the economy devoted to health care. …
Although the document explicitly applies to criminal investigations, Jampol said the questions it asks of compliance programs “could also apply to civil investigations, and civil negotiations” with the DOJ.
Jampol added that corporate attention to DOJ compliance concerns can pay dividends “in terms of the resolution you get with the DOJ.” Cooperation “is definitely rewarded” by the DOJ, Jampol said, and this guidance “provides a roadmap for discussions with the DOJ.”
Ms. Jampol's comments have also recently appeared in the Bloomberg BNA Health Care Blog.
